1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation

FDA Targets DermaTox Maker In Year’s First Published Warnings To Cosmetics Firms

 
• By Ryan Nelson

Healthy Habits reacts indignantly to FDA’s warning about testimonials for DermaTox products featured on its website, which the agency says identify the items as unapproved drugs. Aegeia Skin Care also receives a warning letter for structure/function and disease-treatment claims on its facial- and body-care products.

StormuSkyWarningSign_1200x675

FDA’s warning letter activity in the cosmetics space appeared to drop off steeply last fall, with not a peep from the agency for months, but newly published letters signal FDA’s continued surveillance of the marketplace for excessive claims on skin-care products.

Agency officials indicated last year in exchanges with lawmakers that the roughly 30 warning letters to skin-care companies in 2016...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

FDA Urged To Issue Formaldehyde Rule As California Finds Non-Compliance With State Ban

 
• By Lauren Nardella

Stakeholders are still waiting for the US FDA to issue its widely anticipated proposed rule to prohibit formaldehyde and formaldehyde releasers from hair smoothing or straightening products.

Cloudy Tariff Conditions Expected To Linger In US

 
• By Malcolm Spicer

White House announces president extends deadline he set in April for other countries to make new tariff deals from July 9 to Aug. 1, when the administration will start sending letters warning other countries that higher tariffs could take effect.

US FDA’s Tough Talk On Talc: Regulating In An Echo Chamber

 
• By Michael McCaughan

An FDA “expert roundtable” on talc produced a new talking point on a potential drug safety risk, but the basis of that claim is difficult to determine.